Metraipolis › archive › dc_ac181589be88

Efficacy and Safety of Teclistamab in Relapsed/Refractory Multiple Myeloma: 2-Year Follow-Up From MajesTEC-1 China Cohort — Europe PMC PMID:42534634

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42534634
DOI
10.1002/jha2.70340
License (as archived)
solo-consultazione
Archived
2026-10-17T07:22:44.547Z
SHA-256 of the archived text
4d4f4577ce3e02e8447a69ae06eb468bb20670fad471626c7b70f2e2d8eda176
Stable URL of this page
https://metraipolis.com/documento/dc_ac181589be88

How to cite

Efficacy and Safety of Teclistamab in Relapsed/Refractory Multiple Myeloma: 2-Year Follow-Up From MajesTEC-1 China Cohort — Europe PMC PMID:42534634 — Europe PMC (en), https://europepmc.org/article/MED/42534634 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ac181589be88 (Metraipolis archive dc_ac181589be88, sha256 4d4f4577ce3e02e8447a69ae06eb468bb20670fad471626c7b70f2e2d8eda176)
BibTeX
@misc{dcac181589be88,
  title = {Efficacy and Safety of Teclistamab in Relapsed/Refractory Multiple Myeloma: 2-Year Follow-Up From MajesTEC-1 China Cohort — Europe PMC PMID:42534634},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42534634},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ac181589be88; sha256 4d4f4577ce3e02e8447a69ae06eb468bb20670fad471626c7b70f2e2d8eda176},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42534634. Agents can read the archived copy with the MCP tool read_document.